Veterans Special Report

HBOT Conversations:

Dr. Hemal Mehta & Fasting (Part 2)

Dr. Hemal Mehta, MD is a Medical Director and an Independent Medical Examiner who focuses on pain management through a Regenerative medicine approach. Dr. Mehta is Board Certified in Physical Medicine and Pain Management. He received his Doctor of Medicine Degree from Ross University School of Medicine and completed his residency at East Carolina. He is the Medical Director of Vibrant Health of North Carolina, Tennessee Integrative Pain Institute, and TN Integrative Healthcare:  Musculoskeletal and Regenerative Center; additionally, Dr. Mehta is the attending physician at Nashville Regenerative Orthopedics. Dr. Mehta is the 2013 recipient of the Inaugural Patient Appreciation Award at Nashville Academy of Medicine, and the 2004 Research Resident of the Year for East Carolina University. Dr. Mehta has extensive experience with stem cell proliferation, and angiogenesis.  He has incorporated Ozone Injection Therapy, PRP (Platelet-Rich Plasma) Injections, Hyperbaric Oxygen Therapy and Regenerative Matrix and Regenerative Medicine Procedures – to name a few – into his integrative wellness & longevity medical practices.

Subscribe. Join the discussion. Share the hope.

Watch the Podcast

HBOT News Network welcomes back Dr. Hemal V. Mehta, M.D.; Medical Director of Vibrant Health of North Carolina to continue our discussion on fasting.  In this segment, Dr. Mehta discusses the benefits of fasting and Hyperbaric Oxygen Therapy as a natural, holistic and alternative therapy to eradicate cancer.

di Girolamo & Dr. Mehta examine the use of Vitamin C IV therapy for cancer, and how the combination of Vitamin C IV therapy, fasting and oxygen therapy – especially in the form of Hyperbaric Oxygen Therapy – has been known to put patients in remission and completely eliminate some very serious cancers. Dr. Mehta describes Hyperbaric Oxygen as a “game changer” when adding it into a cancer treatment protocol. He explains that as doctors they are trained to look at chemotherapy first to treat cancer, but there are many holistic ways to help a cancer patient shrink the tumors, stop the spread and live a longer life. He agrees that HBOT would be a great option to help cancer patients on their healing journey.

Diet is another holistic way to treat cancer.  A water fast that puts the body in a ketogenic state, or a ketogenic organic diet are all ranked high as ideal ways to use alternative, natural methods for cancer and pain relief.

Dr. Mehta tells a personal story of his past that involved his father’s diagnosis of papillary thyroid cancer, and how it was the holistic and natural methods Dr. Mehta recommended that gave him extended life. Vitamin C Therapy, consuming organic wheatgrass daily, and daily deep breathing techniques to increase oxygen levels all contributed to him living 3 years longer than his prognosis. After massive shrinkage of the tumors during those 3 years; his father was convinced by an Ocologist to undergo chemotherapy in hopes that it would completely eradicate the cancer from his body.  The chemotherapy caused cardio toxicity and unfortunately ultimately lead to Dr. Mehta’s father passing away.

di Girolamo suggests that viewers watch Research Rundown Episode 16: The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer. This is a popular Research Rundown where our host, Ed di Girolamo, analyzes a study led by researcher, Dominic D’Agostino.  The benefit of combining ketogenic diet with Hyperbaric Oxygen Therapy (HBOT) for metastatic cancer treatment is some very exciting research in the world of HBOT, cancer research, and fasting! This particular research and Dominic’s involvement to help prove that cancer can be eliminated (and maybe even cured) by combining a heavy ketogenic diet and Hyperbaric Oxygen Therapy is further discussed in this HBOT News Conversations episode with Dr. Mehta.

*Pease consult your doctor to see if fasting is right for you.

Guest

Robert Beckman

Dr. Hemal Mehta

Dr. Hemal Mehta specializes in non-opioid treatment for joint pain, osteoarthritis, spine pain and neuropathy. He is a board-certified Physical Medicine and Rehabilitation physician whose goal for patients is to reduce pain while increasing their level of function & quality of life. He received his Doctor of Medicine Degree from Ross University School of Medicine and completed his residency at East Carolina. Dr. Mehta is the Medical Director of Vibrant Health of North Carolina, Tennessee Integrative Pain Institute, and TN Integrative Healthcare:  Musculoskeletal and Regenerative Center; additionally, Dr. Mehta is the attending physician at Nashville Regenerative Orthopedics. He is the 2013 recipient of the Inaugural Patient Appreciation Award at Nashville Academy of Medicine, and the 2004 Research Resident of the Year for East Carolina University. He is a member of the American Academy of Physical Medicine & Rehabilitation, American Society of Interventional Pain Physicians, and American Association of Neuromuscular and Electrodiagnostic Medicine.

Dr. Mehta has extensive experience with stem cell proliferation and angiogenesis. For years he has incorporated Hyperbaric Oxygen Therapy into his integrative approach for pain management and rehabilitation, and he has also preformed the following procedures fluoroscopically: Translaminar Cervical and Lumbar ESI, Transforaminal Lumbar ESI, Lumbar Selective Nerve Root Blocks, Stellate Ganglion Blocks, Lumbar Sympathetic Blocks, SIJ injections, Hip Joint Injections, Piriformis Injections, Cervical and Lumbar Facet Joint Injections, Medial Branch Nerve Blocks, Radiofrequency Ablation of Medial Branch Nerve, Discography, Percutaneous Disc Decompression/ Intradiscal Injections, Spinal Cord Stimulator Lead Trial, PRP/ Regenerative Matrix/ Regenerative Medicine Procedures for Spine, Peripheral Joints, and Nerves, P-Shot/O-shot, Juvederm Anti-aging, and Ozone Injection Therapy.

Subscribe Now, It’s Free!

[contact-form-7 id="65934" title="Subscribe"]

Recent HBOT News

Clinical Trial – Fixed Dose Spinal Bupivacaine for Cesarean Delivery

by | Jul 24, 2017 | , ,

The study is designed to compare the effectiveness of spinal anesthesia performed with fixed
dose of hyperbaric bupivacaine regardless of patient’s height and weight and anesthesia with
the dose of bupivacaine that is adjusted to their height. Our clinical experience shows that
spinal anesthesia using specific, relatively high dose of hyperbaric bupivacaine combined
with opioid is very effective, regardless of parturient’s weight and height, provides very
good surgical conditions and assures patient’s comfort while the rate of anesthesia – related
complications is similar or less. Therefore, using height-adjusted protocols, although
preferred in some centres, might not be necessary in order to provide good anaesthesia for
cesarean delivery. Fixed dose regimen may have some additional advantages in obstetric
anesthesia settings, as many of cesareans are performed out of hours, giving less room for
mistakes in less experienced hands.

Two groups of parturients undergoing cesarean section are to be compared: anesthetized with
fixed-dose regimen (intervention group) and anesthetized with height-adjusted dose regimen
(control group). Patients are going to be randomized to one of the above groups, two
anesthetists will be involved in anesthetic procedure: anesthetist that looks after the
patient throughout the procedure will be blinded to the dose of anesthetic given
intrathecally. Therefore his judgment of anesthetic effectiveness is not going to be biased
and all patients will receive the same perioperative care in terms of fluid therapy,
management of possible anesthesia – related complications and postoperative pain control.

Rate of effective spinal anesthetics, defined as adequate block level and no need for
additional intraoperative analgesia has been established as primary outcome measure.
Secondary outcome measures are rate of complications and amount of opioids used
postoperatively. These are going to be statistically compared.